References
- Krumholz A. Driving and epilepsy: a historical perspective and review of current regulations. Epilepsia 1994; 35(3): 668–74
- Hennessy MJ, Elwes RD, Honavar M, et al. Predictors of outcome and pathological considerations in the surgical treatment of intractable epilepsy associated with temporal lobe lesions. J Neurol Neurosurg Psychiatry 2001; 70(4):450–8
- Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313(3): 145–51
- Mattson RH, Cramer JA, Collins JF. A comparison of valproate and carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327(11): 765–71
- Beydoun A. Safety and efficacy of oxcarbazepine: results of randomized, double-blind trials. Pharmacotherapy 2000; 20(8 Pt 2):S152–8
- Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3(1):70–6
- Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27(3): 195–204
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342(5):314–9
- Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313(7066): 1169–74
- Beydoun A, Uthman BM, Sackellares JC. Gabapentin: pharmacokinetics, efficacy, and safety. Clin Neuropharmacol 1995; 18(6): 469–81
- Beydoun A. Monotherapy trials with gabapentin for partial epilepsy. Epilepsia 1999; 40(Suppl 6):S13–6
- Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40(5):601–7
- Brodie MJ, Richens A, Yuen AW, et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345(8948): 476–9
- Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: a dose-frequency study. The Tiagabine Study Group. Arch Neurol 1997; 54(5):595–601
- Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996; 46(6): 1684–90
- Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55(2): 236–42
- Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety ot zonisamide: results of a multicenter study. Epilepsy Res 1993; 14(2): 165–73
- Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med L997; 337(25): 1807–12
- Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999; 52(9): 1882–7
- Kotani H, Hirai K, Nishiki T, et al. [Zonisamide monotherapy against absence attacks: report of two cases]. No To Hattatsu 1994; 26(4):349–54 (Japanese)
- Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32(2): 157–63
- Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994; 44(4): 601–8
Reference
- Morrell MJ, Guidelines for the care of women with epilepsy. Neurology 1998; 51 (5 Suppl 4): S21–7